Adjuvant Therapy in Stage I Carcinoma of the Breast: The Influence of Multigene Analyses and Molecular Phenotyping
Breast Health International and the Kimmel Cancer Center of Thomas Jefferson University cosponsored a consensus conference that included an international group of experts. Since the adoption of adjuvant chemotherapy for stage I, lymph node-negative breast cancers in 1988, investigators have tried to...
Gespeichert in:
| Veröffentlicht in: | Cancer 2012-04, Vol.118 (8), p.2031-2038 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2038 |
|---|---|
| container_issue | 8 |
| container_start_page | 2031 |
| container_title | Cancer |
| container_volume | 118 |
| creator | SCHWARTZ, Gordon F REIS-FIHLO, Jorge PUSZTAI, Lajos FENTIMAN, Ian S HOLLAND, Roland BARTELINK, Harry RUTGERS, Emiel J. T SOLIN, Lawrence J PALAZZO, Juan |
| description | Breast Health International and the Kimmel Cancer Center of Thomas Jefferson University cosponsored a consensus conference that included an international group of experts.
Since the adoption of adjuvant chemotherapy for stage I, lymph node-negative breast cancers in 1988, investigators have tried to "fine-tune" the treatment criteria. At this consensus conference, the group debated recommendations for adjuvant hormone and cytotoxic chemotherapy in stage I breast cancers.
Discussions during the conference addressed issues of adjuvant therapy for stage I breast cancer and the influence of multigene analyses and molecular phenotyping. The panelists discussed various demographic, morphologic, biologic, and genetic factors expressed by individual tumors and their influence on treatment decisions.
The panel tried to create guidelines for the consideration of adjuvant treatment of these patients, including both hormone and cytotoxic regimens. They also encouraged further research into the molecular analysis of breast cancers and the introduction of clinical trials based on current data, although they concluded that it is too early to add any of those analyses into the decision-making algorithms of recommendations for the treatment of stage I breast cancer. |
| doi_str_mv | 10.1002/cncr.27431 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_993318436</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>993318436</sourcerecordid><originalsourceid>FETCH-LOGICAL-c190t-718599e0ec15aeb76c3c612fd4da3eefff4255a156db04c4a360653fad246873</originalsourceid><addsrcrecordid>eNpF0E1r20AQBuAlpNSu00t-QNlLCBTk7KfWys0xaWuwSSA-9CbGq1lbZr1ydqWA_33kxm1hYBjm4T28hFxzNuaMiTsbbBwLoyS_IEPOCpMxrsQlGTLGJplW8veAfElp159GaPmZDISQhZA5H5I4rXbdG4SWrrYY4XCkdaAvLWyQzukMoq1DswfaONpukT5EhNTenyydB-c7DBZPz2Xn23qDAek0gD8mTBRCRZeNR9t5iPR5i6Fpj4c6bK7IJwc-4dfzHpHVj8fV7Fe2ePo5n00XmeUFazPDJ7ookKHlGnBtcittzoWrVAUS0TmnhNbAdV6tmbIKZM5yLR1UQuUTI0fk9iP2EJvXDlNb7utk0XsI2HSpLAop-UTJvJffP6SNTUoRXXmI9R7iseSsPDVcnhou_zTc42_n2G69x-of_VtpD27OAJIF7yIEW6f_ThtjZD_vZjWEQA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>993318436</pqid></control><display><type>article</type><title>Adjuvant Therapy in Stage I Carcinoma of the Breast: The Influence of Multigene Analyses and Molecular Phenotyping</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library (Open Access Collection)</source><source>Alma/SFX Local Collection</source><creator>SCHWARTZ, Gordon F ; REIS-FIHLO, Jorge ; PUSZTAI, Lajos ; FENTIMAN, Ian S ; HOLLAND, Roland ; BARTELINK, Harry ; RUTGERS, Emiel J. T ; SOLIN, Lawrence J ; PALAZZO, Juan</creator><creatorcontrib>SCHWARTZ, Gordon F ; REIS-FIHLO, Jorge ; PUSZTAI, Lajos ; FENTIMAN, Ian S ; HOLLAND, Roland ; BARTELINK, Harry ; RUTGERS, Emiel J. T ; SOLIN, Lawrence J ; PALAZZO, Juan ; Consensus Committee ; and the Consensus Committee</creatorcontrib><description>Breast Health International and the Kimmel Cancer Center of Thomas Jefferson University cosponsored a consensus conference that included an international group of experts.
Since the adoption of adjuvant chemotherapy for stage I, lymph node-negative breast cancers in 1988, investigators have tried to "fine-tune" the treatment criteria. At this consensus conference, the group debated recommendations for adjuvant hormone and cytotoxic chemotherapy in stage I breast cancers.
Discussions during the conference addressed issues of adjuvant therapy for stage I breast cancer and the influence of multigene analyses and molecular phenotyping. The panelists discussed various demographic, morphologic, biologic, and genetic factors expressed by individual tumors and their influence on treatment decisions.
The panel tried to create guidelines for the consideration of adjuvant treatment of these patients, including both hormone and cytotoxic regimens. They also encouraged further research into the molecular analysis of breast cancers and the introduction of clinical trials based on current data, although they concluded that it is too early to add any of those analyses into the decision-making algorithms of recommendations for the treatment of stage I breast cancer.</description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/cncr.27431</identifier><identifier>PMID: 22392361</identifier><identifier>CODEN: CANCAR</identifier><language>eng</language><publisher>Hoboken, NJ: Wiley-Blackwell</publisher><subject>Biological and medical sciences ; Breast Neoplasms - drug therapy ; Breast Neoplasms - genetics ; Breast Neoplasms - pathology ; Chemotherapy, Adjuvant ; Combined Modality Therapy ; Female ; Gene Expression Profiling ; Gynecology. Andrology. Obstetrics ; Humans ; Mammary gland diseases ; Medical sciences ; Neoplasms, Hormone-Dependent - drug therapy ; Neoplasms, Hormone-Dependent - metabolism ; Practice Guidelines as Topic ; Tumors</subject><ispartof>Cancer, 2012-04, Vol.118 (8), p.2031-2038</ispartof><rights>2015 INIST-CNRS</rights><rights>Copyright © 2012 American Cancer Society.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c190t-718599e0ec15aeb76c3c612fd4da3eefff4255a156db04c4a360653fad246873</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>310,311,315,781,785,790,791,23935,23936,25145,27929,27930</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25777377$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22392361$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SCHWARTZ, Gordon F</creatorcontrib><creatorcontrib>REIS-FIHLO, Jorge</creatorcontrib><creatorcontrib>PUSZTAI, Lajos</creatorcontrib><creatorcontrib>FENTIMAN, Ian S</creatorcontrib><creatorcontrib>HOLLAND, Roland</creatorcontrib><creatorcontrib>BARTELINK, Harry</creatorcontrib><creatorcontrib>RUTGERS, Emiel J. T</creatorcontrib><creatorcontrib>SOLIN, Lawrence J</creatorcontrib><creatorcontrib>PALAZZO, Juan</creatorcontrib><creatorcontrib>Consensus Committee</creatorcontrib><creatorcontrib>and the Consensus Committee</creatorcontrib><title>Adjuvant Therapy in Stage I Carcinoma of the Breast: The Influence of Multigene Analyses and Molecular Phenotyping</title><title>Cancer</title><addtitle>Cancer</addtitle><description>Breast Health International and the Kimmel Cancer Center of Thomas Jefferson University cosponsored a consensus conference that included an international group of experts.
Since the adoption of adjuvant chemotherapy for stage I, lymph node-negative breast cancers in 1988, investigators have tried to "fine-tune" the treatment criteria. At this consensus conference, the group debated recommendations for adjuvant hormone and cytotoxic chemotherapy in stage I breast cancers.
Discussions during the conference addressed issues of adjuvant therapy for stage I breast cancer and the influence of multigene analyses and molecular phenotyping. The panelists discussed various demographic, morphologic, biologic, and genetic factors expressed by individual tumors and their influence on treatment decisions.
The panel tried to create guidelines for the consideration of adjuvant treatment of these patients, including both hormone and cytotoxic regimens. They also encouraged further research into the molecular analysis of breast cancers and the introduction of clinical trials based on current data, although they concluded that it is too early to add any of those analyses into the decision-making algorithms of recommendations for the treatment of stage I breast cancer.</description><subject>Biological and medical sciences</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - genetics</subject><subject>Breast Neoplasms - pathology</subject><subject>Chemotherapy, Adjuvant</subject><subject>Combined Modality Therapy</subject><subject>Female</subject><subject>Gene Expression Profiling</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Mammary gland diseases</subject><subject>Medical sciences</subject><subject>Neoplasms, Hormone-Dependent - drug therapy</subject><subject>Neoplasms, Hormone-Dependent - metabolism</subject><subject>Practice Guidelines as Topic</subject><subject>Tumors</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpF0E1r20AQBuAlpNSu00t-QNlLCBTk7KfWys0xaWuwSSA-9CbGq1lbZr1ydqWA_33kxm1hYBjm4T28hFxzNuaMiTsbbBwLoyS_IEPOCpMxrsQlGTLGJplW8veAfElp159GaPmZDISQhZA5H5I4rXbdG4SWrrYY4XCkdaAvLWyQzukMoq1DswfaONpukT5EhNTenyydB-c7DBZPz2Xn23qDAek0gD8mTBRCRZeNR9t5iPR5i6Fpj4c6bK7IJwc-4dfzHpHVj8fV7Fe2ePo5n00XmeUFazPDJ7ookKHlGnBtcittzoWrVAUS0TmnhNbAdV6tmbIKZM5yLR1UQuUTI0fk9iP2EJvXDlNb7utk0XsI2HSpLAop-UTJvJffP6SNTUoRXXmI9R7iseSsPDVcnhou_zTc42_n2G69x-of_VtpD27OAJIF7yIEW6f_ThtjZD_vZjWEQA</recordid><startdate>20120415</startdate><enddate>20120415</enddate><creator>SCHWARTZ, Gordon F</creator><creator>REIS-FIHLO, Jorge</creator><creator>PUSZTAI, Lajos</creator><creator>FENTIMAN, Ian S</creator><creator>HOLLAND, Roland</creator><creator>BARTELINK, Harry</creator><creator>RUTGERS, Emiel J. T</creator><creator>SOLIN, Lawrence J</creator><creator>PALAZZO, Juan</creator><general>Wiley-Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20120415</creationdate><title>Adjuvant Therapy in Stage I Carcinoma of the Breast: The Influence of Multigene Analyses and Molecular Phenotyping</title><author>SCHWARTZ, Gordon F ; REIS-FIHLO, Jorge ; PUSZTAI, Lajos ; FENTIMAN, Ian S ; HOLLAND, Roland ; BARTELINK, Harry ; RUTGERS, Emiel J. T ; SOLIN, Lawrence J ; PALAZZO, Juan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c190t-718599e0ec15aeb76c3c612fd4da3eefff4255a156db04c4a360653fad246873</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Biological and medical sciences</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - genetics</topic><topic>Breast Neoplasms - pathology</topic><topic>Chemotherapy, Adjuvant</topic><topic>Combined Modality Therapy</topic><topic>Female</topic><topic>Gene Expression Profiling</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Mammary gland diseases</topic><topic>Medical sciences</topic><topic>Neoplasms, Hormone-Dependent - drug therapy</topic><topic>Neoplasms, Hormone-Dependent - metabolism</topic><topic>Practice Guidelines as Topic</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SCHWARTZ, Gordon F</creatorcontrib><creatorcontrib>REIS-FIHLO, Jorge</creatorcontrib><creatorcontrib>PUSZTAI, Lajos</creatorcontrib><creatorcontrib>FENTIMAN, Ian S</creatorcontrib><creatorcontrib>HOLLAND, Roland</creatorcontrib><creatorcontrib>BARTELINK, Harry</creatorcontrib><creatorcontrib>RUTGERS, Emiel J. T</creatorcontrib><creatorcontrib>SOLIN, Lawrence J</creatorcontrib><creatorcontrib>PALAZZO, Juan</creatorcontrib><creatorcontrib>Consensus Committee</creatorcontrib><creatorcontrib>and the Consensus Committee</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SCHWARTZ, Gordon F</au><au>REIS-FIHLO, Jorge</au><au>PUSZTAI, Lajos</au><au>FENTIMAN, Ian S</au><au>HOLLAND, Roland</au><au>BARTELINK, Harry</au><au>RUTGERS, Emiel J. T</au><au>SOLIN, Lawrence J</au><au>PALAZZO, Juan</au><aucorp>Consensus Committee</aucorp><aucorp>and the Consensus Committee</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adjuvant Therapy in Stage I Carcinoma of the Breast: The Influence of Multigene Analyses and Molecular Phenotyping</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>2012-04-15</date><risdate>2012</risdate><volume>118</volume><issue>8</issue><spage>2031</spage><epage>2038</epage><pages>2031-2038</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><coden>CANCAR</coden><abstract>Breast Health International and the Kimmel Cancer Center of Thomas Jefferson University cosponsored a consensus conference that included an international group of experts.
Since the adoption of adjuvant chemotherapy for stage I, lymph node-negative breast cancers in 1988, investigators have tried to "fine-tune" the treatment criteria. At this consensus conference, the group debated recommendations for adjuvant hormone and cytotoxic chemotherapy in stage I breast cancers.
Discussions during the conference addressed issues of adjuvant therapy for stage I breast cancer and the influence of multigene analyses and molecular phenotyping. The panelists discussed various demographic, morphologic, biologic, and genetic factors expressed by individual tumors and their influence on treatment decisions.
The panel tried to create guidelines for the consideration of adjuvant treatment of these patients, including both hormone and cytotoxic regimens. They also encouraged further research into the molecular analysis of breast cancers and the introduction of clinical trials based on current data, although they concluded that it is too early to add any of those analyses into the decision-making algorithms of recommendations for the treatment of stage I breast cancer.</abstract><cop>Hoboken, NJ</cop><pub>Wiley-Blackwell</pub><pmid>22392361</pmid><doi>10.1002/cncr.27431</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0008-543X |
| ispartof | Cancer, 2012-04, Vol.118 (8), p.2031-2038 |
| issn | 0008-543X 1097-0142 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_993318436 |
| source | MEDLINE; Access via Wiley Online Library; EZB-FREE-00999 freely available EZB journals; Wiley Online Library (Open Access Collection); Alma/SFX Local Collection |
| subjects | Biological and medical sciences Breast Neoplasms - drug therapy Breast Neoplasms - genetics Breast Neoplasms - pathology Chemotherapy, Adjuvant Combined Modality Therapy Female Gene Expression Profiling Gynecology. Andrology. Obstetrics Humans Mammary gland diseases Medical sciences Neoplasms, Hormone-Dependent - drug therapy Neoplasms, Hormone-Dependent - metabolism Practice Guidelines as Topic Tumors |
| title | Adjuvant Therapy in Stage I Carcinoma of the Breast: The Influence of Multigene Analyses and Molecular Phenotyping |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-11T01%3A23%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adjuvant%20Therapy%20in%20Stage%20I%20Carcinoma%20of%20the%20Breast:%20The%20Influence%20of%20Multigene%20Analyses%20and%20Molecular%20Phenotyping&rft.jtitle=Cancer&rft.au=SCHWARTZ,%20Gordon%20F&rft.aucorp=Consensus%20Committee&rft.date=2012-04-15&rft.volume=118&rft.issue=8&rft.spage=2031&rft.epage=2038&rft.pages=2031-2038&rft.issn=0008-543X&rft.eissn=1097-0142&rft.coden=CANCAR&rft_id=info:doi/10.1002/cncr.27431&rft_dat=%3Cproquest_cross%3E993318436%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=993318436&rft_id=info:pmid/22392361&rfr_iscdi=true |